Acrivon Therapeutics(ACRV) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects • ...